Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis

Lugain Alkurdi (1) , François Virard (1) , Béatrice Vanbervliet (1) , Kathrin Weber (1) , Florent Toscano (1) , Marc Bonnin (1) , Nolwenn Le Stang (2, 3) , Sylvie Lantuejoul (4, 3) , Olivier Micheau (5) , Toufic Renno (1) , Serge Lebecque (1, 6) , Yann Estornes (1)

1 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
2 ANTICIPE - Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers
3 Centre Léon Bérard [Lyon]
4 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
5 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
6 HCL - Hospices Civils de Lyon

Toll-like receptor 3 (TLR3) mediates innate immune responses by sensing viral dsRNA, but also induces apoptosis selectively in cancer cells. Our analysis by immunohistochemistry revealed that TLR3 is frequently overexpressed in 130 non-small cell lung cancer (NSCLC) patients' samples compared with normal bronchial epithelium (P < 0.0001, Mann-Whitney test), supporting the therapeutic potential of TLR3 ligand for this type of cancer. However, a proportion of TLR3-expressing cancer cell lines, including NSCLC, remain resistant to TLR3-mediated apoptosis, and the underlying mechanism of resistance remains unclear. We here investigated the molecular basis conferring resistance to non-transformed vs. transformed cells against TLR3-mediated cell death. In non-transformed epithelial cells cellular FLICE-like inhibitory protein (c-FLIP) and cellular Inhibitor of APoptosis (cIAPs) ubiquitin ligases exerted an efficient double brake on apoptosis signaling. In contrast, releasing only one of these two brakes was sufficient to overcome the resistance of 8/8 cancer cell lines tested. Remarkably, the release of the c-FLIP, but not cIAPs, brake only results in the sensitization of all human cancer cells to TLR3-mediated apoptosis. Taking advantage of the difference between transformed and non-transformed cells, we developed a rational strategy by combining the chemotherapeutic agent paclitaxel, which decreases c-FLIP expression, with TLR3 ligand. This combination was highly synergistic for triggering apoptosis in cancer cells but not in non-transformed cells. In vivo, the combination of paclitaxel with dsRNA delayed tumor growth and prolonged survival in a mouse xenograft lung tumor model. In conclusion, combining the release of the c-FLIP brake with TLR3 ligand synergizes to selectively kill cancer cells, and could represent an efficient and safe therapy against TLR3-expressing cancers such as NSCLC.

Mots clés: Toll-like receptor 3 (TLR3)

Domaines: Cancer

Lugain Alkurdi, François Virard, Béatrice Vanbervliet, Kathrin Weber, Florent Toscano, et al.. Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis. Cell Death and Disease, 2018, 9 (9), pp.874. ⟨10.1038/s41419-018-0850-0⟩. ⟨hal-01871291⟩